MedTrace Logo

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

NCT02007252 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the study was to provide data to enable decisions regarding the further development of ACZ885 for subjects with abdominal aortic aneurysms. The design of this study addressed the primary objective of evaluating the change in aneurysmal size in subjects with AAA as a result of treatment with ACZ885.

Conditions

  • Abdominal Aortic Aneurysm (AAA)

Interventions

DRUG

ACZ885

ACZ885 150 mg liquid pre-filled syringes were administered s.c..

DRUG

Placebo

Matching placebo liquid pre-filled syringes were administered s.c..

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States
  • Denmark
  • Netherlands
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02007252 on ClinicalTrials.gov